Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
4.243
Zitationen
18
Autoren
2018
Jahr
Abstract
Atezolizumab plus nab-paclitaxel prolonged progression-free survival among patients with metastatic triple-negative breast cancer in both the intention-to-treat population and the PD-L1-positive subgroup. Adverse events were consistent with the known safety profiles of each agent. (Funded by F. Hoffmann-La Roche/Genentech; IMpassion130 ClinicalTrials.gov number, NCT02425891 .).
Ähnliche Arbeiten
Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/<i>neu</i>Oncogene
1987 · 11.670 Zit.
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
2004 · 11.441 Zit.
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 · 11.424 Zit.
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
2004 · 9.373 Zit.
Cell Signaling by Receptor Tyrosine Kinases
2010 · 7.799 Zit.
Autoren
Institutionen
- Queen Mary University of London(GB)
- New York University(US)
- University of California, San Francisco(US)
- University Hospital Heidelberg(DE)
- Heidelberg University(DE)
- Hospital São Lucas da PUCRS(BR)
- Pontifícia Universidade Católica do Rio Grande do Sul(BR)
- Aichi Cancer Center(JP)
- Institut Curie(FR)
- Universidade de São Paulo(BR)
- Seoul National University Hospital(KR)
- Florida Cancer Specialists & Research Institute(US)
- Roche (Switzerland)(CH)
- Dana-Farber Cancer Institute(US)
- The University of Melbourne(AU)
- Peter MacCallum Cancer Centre(AU)
- Bloomberg (United States)(US)